- Home
- COKE vs MDGL Comparison
COKE vs MDGL Comparison
Compare COKE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COKE | MDGL |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 11.5B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | COKE | MDGL |
|---|---|---|
| Price | $167.96 | $526.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $674.45 |
| AVG Volume (30 Days) | ★ 518.2K | 257.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 156.81 | 41.32 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $7,228,055,000.00 | $180,133,000.00 |
| Revenue This Year | N/A | $58.39 |
| Revenue Next Year | N/A | $48.55 |
| P/E Ratio | $135.31 | ★ N/A |
| Revenue Growth | ★ 4.76 | N/A |
| 52 Week Low | $105.21 | $265.00 |
| 52 Week High | $1,183.56 | $615.00 |
Technical Indicators
Market Signals| Indicator | COKE | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 53.44 |
| Support Level | $159.86 | $502.45 |
| Resistance Level | $214.00 | $556.79 |
| Average True Range (ATR) | 10.04 | 21.98 |
| MACD | -3.97 | -0.50 |
| Stochastic Oscillator | 12.28 | 51.98 |
Price Performance
Historical ComparisonAbout COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets, and manufactures nonalcoholic beverages. It offers a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages, and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and non-carbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. The Company has two operating segments: Nonalcoholic Beverages and All Other. Key revenue is generated from Nonalcoholic Beverages.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.